Study directory

Mental health studies with practical context.

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
1743studies shown
Showing 229-240 of 1,743
Drug study icon
CompletedEUCTR 2011-000778-71

A Multicenter, Randomized, Double-Blind, Active Controlled, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients with Treatment Resistant Major Depress...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom
DepressionDrugA study involving a medication or substance.
Countries
United Kingdom, Austria, Italy, ...
Sponsor
Bristol-Myers Squibb International Corporation
Condition
Depression
Drug study icon
CompletedEUCTR 2007-002111-82

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS® methylphenidate (54 and 72 mg/day) i...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom
ADHDDrug
Countries
France, United Kingdom, Belgium, ...
Sponsor
Janssen-Cilag International N.V., Turnhoutseweg 30, B-2340 Beerse, Belgium
Condition
ADHD
Drug study icon
CompletedEUCTR 2017-004602-17

A Multicentre, 8-week, Single-arm, Open-label, Pragmatic Trial to Explore Acceptance and Performance of Using a Digital Medicine System with Healthcare Professionals and Adult Subjects with Schizo...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom
SchizophreniaDrug
Countries
United Kingdom
Sponsor
Otsuka Pharmaceutical
Condition
Schizophrenia
Behavioral study icon
CompletedNCT03126526

A Multimodal Outcome Study of Eating disorders

This summary needs review. Please check the official study record and contact the research team for details.

In United Kingdom
Eating disordersBehavioralFrom 18 Years to 60 Years
Countries
United Kingdom
Sponsor
King's College London
Condition
Eating disorders
Drug study icon
CompletedNCT01923025

A PET Study With RO5545965 in Healthy Male Volunteers

This summary needs review. Please check the official study record and contact the research team for details.

In United Kingdom
SchizophreniaDrugFrom 25 Years to 50 Years
Countries
United Kingdom
Sponsor
Hoffmann-La Roche
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2018-003825-27

A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom
SchizophreniaDrugFrom 18 Years to 55 Years
Countries
United States, United Kingdom, Germany, ...
Sponsor
Biogen Idec Research Limited
Condition
Schizophrenia
Drug study icon
CompletedEUCTR 2015-002007-29

A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Subjects with Major Depressive Di...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom
Depression, AnxietyDrug
Countries
United Kingdom, Spain
Sponsor
Janssen-Cilag International NV
Condition
Depression, Anxiety
Drug study icon
Active Not RecruitingNCT06809595

Study of MM120 for Generalized Anxiety Disorder (Panorama)

This study is active but not recruiting in the United States, in France, in the United Kingdom, .... It focuses on anxiety.

In United Kingdom
AnxietyDrugFrom 18 Years to 74 Years
Countries
United States, France, United Kingdom, ...
Sponsor
Definium Therapeutics US, Inc.
Condition
Anxiety
Drug study icon
CompletedEUCTR 2009-018161-12

A Phase 3, Double-blind, Placebo-controlled, Multicentre, Randomised withdrawal, Long-term Maintenance of Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adol...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom
ADHDDrug
Countries
United Kingdom, Belgium, Germany, ...
Sponsor
Shire Development Inc
Condition
ADHD
Drug study icon
CompletedEUCTR 2011-004668-31

A Phase 3, Open-label, Multicentre, Protocol to Provide Access to Guanfacine Hydrochloride Extended Release for European Subjects with Attention-deficit/Hyperactivity Disorder (ADHD) who Participat...

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments.

In United Kingdom
ADHDDrug
Countries
United Kingdom, Belgium, Austria, ...
Sponsor
Shire Pharmaceutical Development Ltd
Condition
ADHD
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.